Abstract

A series of novel pyrrolidine sulfonamide derivatives were designed, synthesized and screened in silico for their β-gluscosidase inhibitory activity. The results showed that the pyrrolidine derivatives exhibited moderate inhibitory activity against human β-gluscosidases inhibitors. The structure-activity relationships were also briefly discussed. The studies indicated that compounds of Series B with imidazole sulfonyl group were the most potent inhibitors compared to the other compounds under investigation.